 |
|
|
Table 3. Use of Helixor in Cancer Treatment: Clinical Reports Describing Therapeutic Endpointsa
|
Reference Citation(s)
|
Type of Study
|
Type(s) of Cancer
|
No. of Patients: Enrolled; Treated; Controlb
|
Strongest Benefit Reportedc
|
Concurrent Therapyd
|
Level of Evidence Scoree
|
| [19] |
Randomized trial |
Breast, stages I–III |
692; 192; 274 |
Improved survival |
Yes |
1iiA |
| [17] |
Randomized trial |
Colorectal, metastatic
|
60; 20; 20 |
Improved mean survival |
Yes |
1iiA |
| [18] |
Nonrandomized controlled trialf |
Colorectal, recurrent or metastatic |
40; 19; 20 |
Improved mean survival |
Yesg |
2A |
|
No. = number.
|
|
aSee text and the NCI Dictionary for additional information and definition of terms.
|
|
bNumber of patients treated plus number of patients controlled may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were administered the treatment being studied AND for whom results were reported; historical control subjects are not included in number of patients enrolled.
|
|
cStrongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.
|
|
dChemotherapy, radiation therapy, hormonal therapy, or cytokine therapy administered/allowed at the same time as mistletoe therapy.
|
|
eFor information about levels of evidence analysis and an explanation of the level of evidence scores, see Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.
|
|
fThis trial was planned as a randomized trial; however, the randomization scheme failed.
|
|
gThe patients received either chemotherapy only (n = 20) or chemotherapy plus Helixor (n = 20).
|
References
-
Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol 18 (6): 155-64, 1986.
-
Douwes FR, Kalden M, Frank G, et al.: [Treatment of advanced colorectal carcinoma: efficacy test of the combination of 5-fluorouracil and tetrahydrofolic acid versus 5-fluorouracil and tetrahydrofolic acid in combination with an optimized Helixor treatment]. Dtsch Z Onkol 21 (3): 63-7, 1988.
-
Gutsch J, Berger H, Scholz G, et al.: [Prospective study in radically operated breast cancer with polychemotherapy, Helixor® and untreated controls]. Dtsch Z Onkol 21: 94-101, 1988.
|
|
|
